GE HealthCare and Novo Nordisk: Ultrasound Technology Stocks Rising News ad
The advent of GLP-1 therapies has been a game changer in the medical sector in the field of weight loss and chronic obesity. The GLP-1 market is currently dominated by semaglutide (Ozempic and Wegovy), manufactured by Novo Nordisk A/S New York Stock Exchange: HBO and tirzepatide (Mounjaro and Zepbound), produced Eli Lilly and Co. New … Read more
